



CCM DUOPHARMA BIOTECH BERHAD (524271-W)

(Incorporated in Malaysia)

**UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
FOR THE PERIOD ENDED 31 DEC 2016**

Group	Reserves					Retained Profit RM '000	Total RM '000
	Non-distributable			Distributable			
	Share Capital RM '000	Treasury Shares RM' 000	Share Premium RM '000	Revaluation Surplus RM '000	Translation Reserve RM '000		
At 1 January 2016	139,478	-	194,205	0	(722)	116,757	449,718
Foreign exchange translation differences					291		291
Total other comprehensive income for the period	-	-	-	-	291	-	291
Profit for the year						27,517	27,517
Total comprehensive income for the period	-	-	-	-	291	27,517	27,808
2015 final dividend (5.5 sen per share tax exempt)						(15,343)	(15,343)
2016 interim dividend (2.5 sen per share tax exempt under single tier system)						(6,974)	(6,974)
At 31 Dec 2016	139,478	0	194,205	0	(431)	121,957	455,209



CCM DUOPHARMA BIOTECH BERHAD (524271-W)
(Incorporated in Malaysia)
UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
FOR THE PERIOD ENDED 31 DEC 2016

Group	Reserves					Retained Profit RM '000	Total RM '000
	Share Capital RM '000	Treasury Shares RM' 000	Share Premium RM '000	Revaluation Surplus RM '000	Translation Reserve RM '000		
At 1 January 2015	69,739	(1,578)	13,720	-	-	111,749	193,630
Foreign currency translation differences for foreign operations	-	-	-	-	(722)	-	(722)
Total comprehensive income for the period	-	-	-	-	-	36,391	36,391
Total comprehensive income for the period	69,739	(1,578)	13,720	-	(722)	148,140	229,299
Re-issuance of all treasury shares in open market		1,578	594				2,172
Distribution cost on reissuance of all treasury share in open market			(8)				(8)
2014 final dividend (14.5 sen per share tax exempt under single tier system)						(20,225)	(20,225)
2015 interim dividend (4 sen per share tax exempt under single tier system)						(11,158)	(11,158)
Issuance of ordinary shares pursuant to Right Issue exercise	69,739		181,324				251,063
Distribution cost pursuant to Right Issue exercise (net of tax)			(1,425)				(1,425)
At 31 December 2015	139,478	0	194,205	0	(722)	116,757	449,718

(The Condensed Consolidated Statement of Changes in Equity should be read in conjunction with the Audited Financial Statements for the year ended 31 December 2015 and the accompanying explanatory notes attached to the interim financial statements.)



CCM DUOPHARMA BIOTECH BERHAD (524271-W)
(Incorporated in Malaysia)
UNAUDITED CONDENSED CONSOLIDATED CASH FLOW STATEMENT
FOR THE PERIOD ENDED 31 DEC 2016

	31 Dec 2016	31 Dec 2015
	RM '000	RM '000
Cash flows from operating activities		
Profit before taxation	31,479	47,829
Adjustments for:		
Depreciation of property, plant and equipment	22,199	21,532
Interest income	(4,234)	(1,384)
Finance costs	5,550	3,740
Negative goodwill	-	(1,160)
Provision for warranty	(471)	206
Loss on write off of property, plant and equipment	1,190	596
Net unrealised foreign exchange (gain)/loss	(29)	(811)
<i>Operating profit before changes in working capital</i>	<u>55,684</u>	<u>70,548</u>
Change in inventories	(35,634)	2,663
Change in receivables, deposits and prepayments	5,844	(19,795)
Change in payables and accruals	25,115	(87,885)
<i>Cash generated from operations</i>	<u>51,009</u>	<u>(34,469)</u>
Finance costs paid	(5,550)	(3,740)
Interest income	4,234	1,384
Income tax paid	(12,647)	(12,667)
Net cash generated from operating activities	<u>37,046</u>	<u>(49,492)</u>
Cash flows from investing activities		
Acquisition of property, plant and equipment	(30,340)	(40,004)
Acquisition of intangible assets	(3,917)	(1,413)
Acquisition of subsidiary, net of cash and cash equivalents acquired	-	(108,849)
Proceed from disposal of brand	-	1,600
Net cash used in investing activities	<u>(34,257)</u>	<u>(148,666)</u>
Cash flows from financing activities		
Dividends paid to shareholders of the Company	(22,316)	(31,383)
Drawdown of borrowings	11,498	245,490
Proceed from issuance of ordinary shares	-	251,063
Payment of expenses relating to issuance of ordinary share	-	(1,425)
Proceed from sale of treasury shares	-	2,172
Payment of expenses relating to re-issuance of treasury share	-	(8)
Repayment of borrowings	(20,958)	(141,822)
Net cash used in financing activities	<u>(31,776)</u>	<u>324,087</u>
Exchange differences on translation of financial statements of foreign operations	291	(722)
Net decrease in cash and cash equivalents	(28,696)	125,207
Cash and cash equivalents at 1 January	143,510	18,303
Cash and cash equivalents as at 31 Dec	<u>114,814</u>	<u>143,510</u>
	-	-
(l) Cash and cash equivalents comprise:		
	<u>RM '000</u>	<u>RM '000</u>
Cash and bank balances	30,336	47,510
High liquid investment with financial institutions	84,478	96,000
	<u>114,814</u>	<u>143,510</u>

(The Condensed Consolidated Cash Flow Statement should be read in conjunction with the Audited Financial Statements for the year ended 31 December 2015 and the accompanying explanatory notes attached to the interim financial statements.)